Latest Health And Beauty News

McPherson’s chief executive and managing director Brett Charlton will step down after more than three years at the helm, with the board beginning an immediate search for his successor. Charlton will remain in the role during a six-month notice period, subject to arrangements agreed with the board.

AMCIL posted a $6.9 million profit for FY2026 while its portfolio returned negative 10%, underperforming the ASX 200. The company cut dividends to 4.0 cents fully franked, reshuffled holdings, and welcomed Alison Gibson as new CEO.

Wesfarmers outlines a bold growth and productivity agenda centred on AI integration, expanding retail footprints, and lithium project progress, underpinning strong shareholder returns and portfolio resilience.

Scentre Group’s first-quarter update reveals robust sales and visitation gains, near-full occupancy, and steady capital management moves, underpinning its confidence in 2026 earnings growth despite geopolitical uncertainties.

Osteopore Limited has secured non-exclusive distribution rights for an injectable regenerative bone filler across Southeast Asia, marking a strategic expansion of its orthopaedic product portfolio and opening new revenue channels.

McPherson’s Limited has unveiled a sweeping two-year transformation, streamlining its brand portfolio and adopting a scalable third-party logistics model to drive growth and improve financial stability.

McPherson’s Limited updates shareholders on its ongoing transformation journey, reporting modest core brand growth in FY25 and outlining a strategic outlook for FY26 focused on sustainable expansion and operational efficiency.

Bod Science Limited has reported a notable profit turnaround for FY2025, driven by medicinal cannabis sales growth, while navigating a complex Deed of Company Arrangement and a proposed backdoor listing with Biortica Agrimed Limited.

Biome Australia has partnered with Green Cross Health to launch its Activated Probiotics across New Zealand’s largest pharmacy network, marking a pivotal step in its international growth strategy.

McPherson’s Limited reported a 3.9% revenue decline in FY25 due to shedding non-strategic brands, while its core health and beauty brands grew modestly. The company’s transition to a wholesaler and third-party logistics model marks a pivotal shift aimed at long-term growth despite a widened net loss.

Star Combo Pharma has reported a remarkable jump in profit for FY2025, driven by strong revenue growth and a settled insurance claim, while declaring its second dividend and planning production expansion.

Pharmx Technologies Limited reported a 13% increase in revenue for FY25, driven by expanded supplier-pharmacy connections and Marketplace platform growth, while profit before tax declined due to significant investments in new technology platforms.